Efficacy of mobilisation with movement in chronic shoulder pain: protocol for a systematic review and meta-analysis of controlled trials

Arnstein Storås, Fabian Lillebostad, Sturla Haslerud, Jon Joensen, Jan Magnus Bjordal, Martin Bjørn Stausholm

INTRODUCTION

Shoulder pain currently affects 18%–26% of adults, making it one of the most common musculoskeletal problems.1 The symptoms involved are often persistent and disabling and the reason for sick leave.1 Although there are numerous ways shoulder disorders occur, atraumatic shoulder disorders, including subacromial pain syndrome (SAPS) and adhesive capsulitis (AC), predominate in numbers.1

SAPS involves pain in the acromial area and it is typically worsening while lifting the arm. The pathology is sometimes referred to as shoulder impingement syndrome, however, recent studies show that it is not associated with impingement of tissues, and hence SAPS is a better term for it.2 SAPS is the most common shoulder disorder, accounting for approximately 36% of all shoulder diagnoses.3 The risk of SAPS is increased by smoking, sleeping in the decubitus position4 and overhead sports, such as handball play.5

AC is an idiopathic inflammatory shoulder disorder with excessive adhesive (scar) formation and restricted range of motion. The prevalence of AC has been estimated to be 2%–5% in the general population and 13.4% in persons with diabetes mellitus.6,7 Furthermore, AC most frequently occurs in persons aged 40–60 years and especially in females.7

Unfortunately, only 50% of patients who begin a course of treatment for shoulder pain are cured within 6 months.8 There is currently a debate going on about whether shoulder examination should focus on finding a specific anatomical structure as a pain generator. Other authors have developed non-specific (non-anatomical) examination

ABSTRACT

Introduction Shoulder pain affects approximately one in four adults and is thus one of the most common musculoskeletal problems. Only 50% of patients who begin treatment for shoulder pain are cured within 6 months. There is a need for systematic reviews to estimate the effectiveness of shoulder treatments. We decided to evaluate the effect of mobilisation with movement (MWM) on chronic shoulder pain in a systematic review.

Methods and analysis The review will include controlled trial articles identified via five electronic databases (PubMed, Embase, Cumulative Index to Nursing and Allied Health Literature, Physiotherapy Evidence Database and Cochrane Central Register of Controlled Trials), reference lists, citations searches and experts in the field. Only controlled trials involving participants with a mean duration of pain of ≥3 months, in which the effectiveness of MWM has been compared with non-invasive treatments, sham mobilisation or wait-and-see will be included. The included trials will be synthesised with random effects meta-analyses. Risk-of-bias will be assessed with the Physiotherapy Evidence Database 0–10 point scale.

Ethics and dissemination The review does not require ethics approval as it is based on anonymised data from trial reports. The results of the review will be disseminated through a peer-reviewed publication.

PROSPERO registration number CRD42018109380.

Strengths and limitations of this study

- This review will be conducted in conformance with a detailed a priori published protocol, which includes, for example, a plan for estimating standard deviations for the meta-analyses.
- We will search for eligible trial articles using five electronic literature databases, reference lists of relevant trial and review reports, citations and experts in the field.
- The selection of trials, risk-of-bias assessment and data extraction will be handled in a two-person procedure.
- Only studies reported in English and Nordic languages will be considered for inclusion.
- There will be no comparisons between shoulder mobilisation with movement and surgery.

To cite: Storås A, Lillebostad F, Haslerud S, et al. Efficacy of mobilisation with movement in chronic shoulder pain: protocol for a systematic review and meta-analysis of controlled trials. BMJ Open 2021;11:e049563. doi:10.1136/bmjopen-2021-049563

Received 28 January 2021
Accepted 09 August 2021

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
1Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway
2Department of Public Health, University of Stavanger, Stavanger, Norway
Correspondence to Martin Bjørn Stausholm; m.b.stausholm@gmail.com

Check for updates
systems with treatment algorithms. One of these systems is using broader terms to classify patients in one out of three categories: irritable SAPS, non-irritable SAPS and degenerative SAPS. In this system, only the irritable SAPS group is offered local treatment like cryotherapy to reduce pain and irritation.

Manual therapy is also suggested as a pain-relieving treatment option in this system. Manual therapy is used in the treatment of peripheral joint pain, and Brian Mulligan’s technique mobilisation with movement (MWM) is one variant. According to Mulligan, the correction of positional faults in and around the joint by MWM may lead to a resolution of the symptoms. The technique for peripheral joints combines continuous manual application of ‘gliding’ force to a joint, with the purpose of correcting these positional faults with simultaneous physiological movement of the joint, performed actively by the patient or passively by the therapist. To achieve a desired result, many repetitions of painless MWM are needed, sometimes combined with overpressure from the therapist. It has been argued that correct application of these techniques would cause the patient’s pain on movement to disappear immediately after the first treatment session. Mulligan’s original ‘positional fault’ theory for the effect of MWM was based on a notion of ‘misalignment’ between the joint’s articular surfaces, which arise secondary to an injury and cause an incorrect glide in the joint. This would produce pain, stiffness and/or weakness. However, this biomechanical theory has not been verified. It has been hypothesised that the effects of MWM are neurophysiological. Mechanoreceptors are excited in the joint capsule, which in turn modulates central nervous actions by inhibiting incoming nociceptive information. This ‘gate control’ mechanism suppresses pain. In addition, stimulation of other centres, such as the dorsal periaqueductal grey matter region, produces a deep and selective analgesia. A more recently proposed theory is that pain reduction by MWM concerns habituating and excitation. According to this theory, patients who experience pain during movement may develop fear-avoidance behaviour. Consequently, progressive exposure to the feared movements may desensitise the nervous system through actions of habituation.

The effectiveness of MWM on peripheral joint pain has been systematically reviewed by Hing et al, Westad et al and Stathopoulos et al. Several relevant trials have been published after the review by Hing et al and yet the review by Westad et al only includes a single trial on shoulder pain. Only one investigator selected the trials for the review by Westad et al and this may be the reason why it lacks some eligible trials. Only the review by Stathopoulos et al features a meta-analysis, however, they systematically excluded all relevant trials published before year 2008. Therefore, we decided to conduct a new systematic review and meta-analysis on the topic, and we decided to focus on chronic pain of the shoulder due to the complexity of this joint. We will use the latest definition of chronic pain adopted by WHO, that is, pain for at least 3 months. Our hypothesis is that MWM can reduce pain and disability and increase quality of life (QoL) and shoulder range of motion in persons with chronic shoulder pain.

**METHODS**

This protocol is reported in accordance with the Preferred Reporting Items of Systematic Reviews and Meta-Analyses for Protocols 2015. The search for eligible trial articles is ongoing and the review is expected to be completed by 1 October 2021.

**Literature search and selection of studies**

We will include controlled trials involving participants with mean duration of shoulder pain of ≥3 months, in which the effectiveness of MWM was compared with that of other conservative treatment, sham mobilisation or wait-and-see in terms of pain, self-reported disability, QoL and/or shoulder range of motion. A summary of the eligibility criteria is provided in table 1.

A search for eligible articles indexed in PubMed, Embase and Physiotherapy Evidence Database, Cumulative Index to Nursing and Allied Health Literature and Cochrane Central Register of Controlled Trials was performed on 25 March 2020. The database search strings included synonyms for MWM and shoulder pain. Keywords were added to the search string when optional. The PubMed search string is provided in online supplemental material. The search will be continued by reading reference lists of the eligible trial and relevant review articles, citations and involvement of experts in the field. Only studies reported in English and Nordic languages will be considered for inclusion.

Two reviewers will each independently select the trial articles. Both reviewers will read the titles/abstracts of all the records identified in the search, and any obtainable full-text article will be retrieved if it is judged potential eligible by a reviewer. Both reviewers will evaluate the full texts of all the potentially eligible retrieved articles and make an independent decision to include or exclude each article, with close attention to the eligibility criteria. Selection disagreements will be resolved by discussion.

| Table 1  | Eligibility criteria for studies |
|----------|-------------------------------|
| **PICOS strategy** | **Inclusion criteria** |
| Participants | Persons with shoulder pain in the previous ≥3 months |
| Intervention | Mobilisation with movement |
| Comparison | Conservative treatment, sham mobilisation or no treatment |
| Outcomes | Pain, self-reported disability, quality of life and/or shoulder range of motion |

**Study design** Controlled trials

PICOS, Participants, Intervention, Comparison, Outcomes, Study Design.
Any retrieved ineligible article will be excluded with an explicit reason why.

Risk-of-bias analysis
The included trials will be assessed for risk-of-bias at the outcome level by two independent reviewers using the Physiotherapy Evidence Database 0–10 point scale, as it has been found to be a valid and reliable tool. Risk-of-bias disagreements will be resolved by discussion. The reasons for our risk-of-bias scorings of the included trials will be stated.

Likelihood of publication bias will be assessed with graphical funnel plots if at least 10 trials are available.

Data extraction and meta-analysis
Extraction of the following information will be mandatory: year of publication, number of participants randomised to MWM and control groups, type and duration of interventions, time points of assessments, participant characteristics (age, gender, body mass index, baseline shoulder pain), effect estimates (pain, disability, QoL and shoulder range of motion) and adverse events.

The data extraction will be handled by two reviewers. One reviewer will extract the data independently and another reviewer will check the work for correctness. Data disagreements will be resolved by discussion.

The primary outcome is pain intensity and the secondary outcomes are self-reported disability and QoL and shoulder range of motion. Outcomes of the same nature reported on different scales will be meta-analysed using the Hedges’ g standardised mean difference (SMD). The SMD will be interpreted as follows: SMDs of 0.2, 0.5 and 0.8 represent a small, moderate and large difference, respectively.

Outcomes of the same nature reported on the same scale will be meta-analysed using the mean difference method.

The DerSimonian and Laird version of the random effects meta-analysis model will be utilised. Impact from heterogeneity (inconsistency) on the analyses will be examined using I² statistics. I² values range from 0% to 100%. The I² values will be categorised as low (25%), moderate (50%) and high (75%).

The standard deviations for meta-analysis will be extracted or estimated from other variance data in the following order: (1) standard deviation, (2) standard error, (3) 95% confidence interval, (4) p value, (5) interquartile range, (6) median of correlations, (7) visually from graph or (8) other methods.

The trials may be subgrouped by shoulder pathology, risk of bias, MWM protocols and comparisons.

Patient and public involvement
There was no patient or public involvement in the development of this protocol.

Amendments
Any amendment to this protocol will be reported in the result article.
14 Hing W, Bigelow R, Bremner T. Mulligan's Mobilization with Movement: A Systematic Review. *J Man Manip Ther* 2009;17:39E–66.
15 Stathopoulos N, Dimitriadis Z, Kourmantakis GA. Effectiveness of Mulligan’s mobilization with movement techniques on range of motion in peripheral joint pathologies: a systematic review with meta-analysis between 2008 and 2018. *J Manipulative Physiol Ther* 2019;42:439–49.
16 Treede R-D, Rief W, Barke A, et al. Chronic pain as a symptom or a disease: the IASP classification of chronic pain for the International classification of diseases (ICD-11). *Pain* 2019;160:19–27.
17 Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. *BMJ* 2015;349:g7647.
18 Physiotherapy evidence database scale, 1999. Available: https://pedro.org.au/wp-content/uploads/PEDro_scale.pdf [Accessed 26 Jul 2021].
19 Yamato TP, Maher C, Koes B, et al. The PEDro scale had acceptably high convergent validity, construct validity, and interrater reliability in evaluating methodological quality of pharmaceutical trials. *J Clin Epidemiol* 2017;86:176–81.
20 Higgins JPT, Green S. Cochrane Handbook for systematic reviews of interventions, 2011. Available: http://handbook.cochrane.org/[Accessed 3 Dec 2015].
21 Higgins JPT, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. *BMJ* 2003;327:557–60.